



December 11, 2017
Announcement no. 20

Financial Calendar 2018

February 8, 2018	Quiet period prior to the annual report begins (4 weeks)
March 2, 2018	Deadline for shareholder proposals for the AGM
March 8, 2018	Annual report for 2017
April 13, 2018	Annual General Meeting
April 19, 2018	Quiet period prior to the Interim report begins (2 weeks)
May 3, 2018	Interim report - 3 months 2018
August 2, 2018	Quiet period prior to the Interim report begins (2 weeks)
August 16, 2018	Interim report - 6 months 2018
October 25, 2018	Quiet period prior to the Interim report begins (2 weeks)
November 8, 2018	Interim report - 9 months 2018

For further information, please contact:

Gry Husby Larsen, General Counsel
Peter M. Eriksen, CEO
Telephone +45 4529 0000, e-mail investor@bioporto.com



About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.